results miniature hitting mark plaque reduction phase 2 trial failing significantly outperform placebo cognition underlying issue according dr. lon schneider director california alzheimer disease center university southern california plaques not target biomarkers target result hitting change downstream behavior cognition illness course schneider said yeah knocking amyloid far not changing behavior ban2401 saving grace highest dose appeared reduce amyloid improve patient clinical results come scrutiny ban2401 trial 70 percent patients getting placebo genetic mutation triples risk alzheimer high dose ban2401 group 30 percent patients mutation called apoe4 explain ban2401 outperform saline injection high dose group skeptics past trials suggest apoe4 carriers